Evotec SE (ETR: EVT)

Market Cap	1.49B
Revenue (ttm)	777.05M
Net Income (ttm)	-171.37M
Shares Out	177.30M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,687,971
Open	8.25
Previous Close	8.32
Day's Range	8.02 - 8.41
52-Week Range	5.06 - 21.69
Beta	1.05
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 11, 2025

About Evotec SE

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exsci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 5,061
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EVT

Financial Performance

In 2023, Evotec SE's revenue was 781.43 million, an increase of 3.99% compared to the previous year's 751.45 million. Losses were -83.91 million, -52.23% less than in 2022.